LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. ENOV
4. AON
5. AZN
6. BLSM
7. GRMN
8. GPRO
9. KRMN
10. TXNM

Go back to LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
(NASDAQ: LIVN) Delayed: 79.63 -0.18 (0.23%)
Previous Close $79.81    52 Week High $63.21 
Open $79.57    52 Week Low $41.17 
Day High $80.63    P/E N/A 
Day Low $78.49    EPS $0.00 
Volume 102,647